Page 2 in Annual Report 2010

Contents Active Biotech in brief Comments from the CEO Directors’ report THE GROUP Cash-flow statement Comprehensive income Financial position Changes in shareholders’ equity THE PARENT COMPANY 3 4 6 13 13 13 13 14 Annual General Meeting The Annual General Meeting of Active Biotech AB (publ) is to be held on Thursday, May 5, 2011 at 5:00 p.m. at Scandic Star Hotel Lund, Glimmervägen 5, Lund, Sweden. Shareholders who wish to participate in the Meeting must (a) be recorded in the register of shareholders maintained by Euroclear Sweden AB (formerly VPC AB) on Thursday, April 28, 2011 and (b), notify the company of their intention to participate in the Meeting not later than 4:00 p.m. on Thursday, April 28, 2011. Shareholders who have trustee-registered shares must temporarily re-register the shares in their own name with Euroclear Sweden to be entitled to participate in the Meeting. This registration must be completed not later than Thursday, April 28, 2011. Accordingly, shareholders must inform the trustee of this request in ample time prior to this date. Notice of participation Notice of participation can be made in writing to Active Biotech AB (publ), Attn. Susanne Jönsson, PO Box 724, SE-220 07 Lund, Sweden, by fax +46 (0)46-19 20 50, by telephone to +46 (0)46-19 20 00 or by e-mail to The notice shall include name, personal/corporate registration number, number of shares held, daytime telephone number and, if applicable, the number of advisors (two at the most) that will accompany the shareholder at the Meeting. The notice of the Annual General Meeting is available in its entirety on the company’s website Income statement Cash-flow statement Statement of comprehensive income Balance sheet Changes in shareholders’ equity Notes to the financial statements Audit report Financial development The share Intellectual property rights Board of Directors and Auditors Management Group Glossary Business concept, goals and business strategy Financial information Interim report (Q1) Annual General Meeting Interim report (Q2) Interim report (Q3) Year-end report for 2011 14 14 14 15 15 16 35 36 37 40 44 45 46 46 Corporate Governance Report 2010 41 April 28, 2011 May 5, 2011 Aug 11, 2011 Nov 3, 2011 Feb 16, 2012 Financial information can be requested from Active Biotech AB, PO Box 724, SE-220 07 Lund, Sweden. Telephone +46 (0)46-19 20 00, fax +46 (0)46-19 11 00. Information can also be obtained from the company’s website This Annual Report contains forward-looking information regarding Active Biotech. Although we believe that our expectations are based on reasonable assumptions, forward-looking statements could be affected by factors causing the actual outcome and trend to differ materially from the forecast. The forward-looking statements comprise various risks and uncertainties. There are significant factors that could cause the actual outcome to differ from that implied by these forward-looking statements, some of which are beyond our control. These include the risk that patent rights might expire or be lost, exchange-rate movements, the risk that research and development operations do not result in commercially successful new products, competition effects, tax risks, effects resulting from the failure of a third party to deliver products or services, difficulties in obtaining and maintaining official approval for products, and environmental responsibility risks.

Page 1 - Active Biotech Annual Report 2010   Page 3 - Active Biotechinbrief Active Biotech currently has five projects in clinical phase,  
To read this myPaper publication you need to have JavaScript activated in your web browser. You also need to have at least Flash Version 6 installed.